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A B S T R A C T
Background and objective: During recent years, some persistent organic pollutants (POPs) have been linked to
atherosclerosis. One group of POPs, the poly- and perﬂuoroalkyl substances (PFASs) have not been investigated
with regard to atherosclerotic plaques.
Methods: Carotid artery atherosclerosis was assessed by ultrasound in 1016 subjects aged 70 years in the
Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Eight PFASs were detected in >
75% of participants' plasma by ultra-performance liquid chromatography coupled to tandem mass spectrometry
(UPLC-MS/MS).
Results: No signiﬁcant linear associations were observed between the PFASs and intima-media thickness
(IMT), or the echogenicity in the intima-media complex (IM-GSM, a marker of lipid inﬁltration in the artery)
when men and women were analyzed together. Neither was occurrence of carotid plaques related to PFASs
levels. However, highly signiﬁcant interactions were observed between some PFASs and sex regarding both IM-
GSM and plaque prevalence. Perﬂuorononanoic acid (PFNA), perﬂuorodecanoic acid (PFDA), and perﬂuor-
oundecanoic acid (PFUnDA), were all related to IM-GSM in a positive fashion in women (p=0.002–0.003),
while these relationships were negative in men. The levels of PFUnDA were signiﬁcantly related to carotid
plaque in women (OR 1.59, 95%CI 1.03–2.43, p=0.03), but not in men (OR 0.93, 95%CI 0.62–1.42, p=0.75).
Conclusions: In this cross-sectional study, a pronounced gender diﬀerence was observed regarding associations
between some PFASs, especially the long-chain PFUnDA, and markers of atherosclerosis, with more
pronounced relationships found in women. These ﬁndings suggest a sex-speciﬁc role for PFASs in athero-
sclerosis.
1. Introduction
Per- and polyﬂuoroalkyl substances (PFASs) are a huge class of
compounds used to manufacture a wide variety of industrial and
household applications due to their unique properties of being both
water and oil repellent. The production of PFASs was initiated in the
late 1940s and ubiquitous amounts of PFASs have since then been
released to the environment (Lindstrom et al., 2011). The most widely
used among the large group of PFASs are the perﬂuoroalkyl sulfonic
acids (PFSAs) and perﬂuoroalkyl carboxylic acids (PFCAs), including
perﬂuorooctane sulfonic acid (PFOS) and perﬂuorooctanoic acid
(PFOA). PFOS and PFOA share the feature of being fully ﬂuorinated,
eight-carbon chain organic acids (C8). However, numerous perﬂuor-
oalkyls with varying carbon chain length, from four carbons to fourteen
carbons (C4-C14), can be detected in various compartments in the
environment (Lau et al., 2007).
Global regulatory actions to control the emissions and production
of PFASs have only recently been implemented for perﬂuorooctane
sulfonate (PFOS) and its precursors which were included in the Annex
B of the 2009 Stockholm Convention (UNEP, 2015). Furthermore,
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voluntary discontinuation agreements from major manufacturers of
PFOS and PFOA have been implemented in the United States and
Western Europe (US EPA, 2006, 2014) . Although recent temporal
studies suggest that these phase-out policies have resulted in reduced
emissions and decreasing concentrations of PFOS and PFOA in
humans and wildlife (Bjerregaard-Olesen et al., 2016; Johansson
et al., 2014; Nost et al., 2014; Okada et al., 2013; Rigét et al., 2013;
Wang et al., 2011; Yeung et al., 2013), it is yet unclear whether the
eﬀect is due to a change in the global production as there is a dynamic
shift in the industrial production of PFASs.
The presence of PFASs in men, women, and children has been
extensively reported (Bjerregaard-Olesen et al., 2016; Frisbee et al.,
2009; Wang et al., 2011) and an integral part of the exposure in the
general population arises through the dietary exposure including
drinking water (Fromme et al., 2009). The bioaccumulation and toxic
potential of perﬂuoroalkyls has been suggested to increase with
increased carbon-chain lengths (Liao et al., 2009; Martin et al.,
2003) and the most frequently detected compounds in the general
population are PFOS and PFOA followed by perﬂuorononanoic acid
(PFNA), and perﬂuorohexane sulfonic acid (PFHxS) (Glynn et al.,
2012; Karrman et al., 2010; Kato et al., 2011; Sundström et al., 2011;
Wang et al., 2011).
A number of adverse health eﬀects have been linked to elevated
levels of PFASs (Steenland et al., 2010a). However, there is no uniform
picture on the cardiovascular eﬀects in response to PFASs exposure,
and most studies up to date have been based on occupational or
accidental settings (Borg et al., 2013; Sakr et al., 2007; Simpson et al.,
2013; Steenland et al., 2010b; Winquist and Steenland, 2014) with a
gender bias in favor of men. However, many studies show uniformly
that certain PFASs are related to high serum cholesterol levels (Nelson
et al., 2010; Skuladottir et al., 2015; Winquist and Steenland, 2014).
Since high serum cholesterol levels are linked to atherosclerosis, it is of
importance to evaluate if cholesterol mediates possible relationships
between PFASs and cardiovascular diseases.
At present, there is limited information on the relationship between
PFASs exposure and atherosclerosis in a gender-balanced sample of the
general population. One study found a relationship between PFOS
levels and the carotid artery intima-media thickness (IMT), especially
in women (Lin et al., 2013). We have recently shown that polychlori-
nated biphenyls (PCBs) are related to atherosclerosis in humans (Lind
et al., 2012b). Animal experiments support that this ﬁnding is causal
(Dalton et al., 2001; Wu et al., 2011). Correspondingly, we hypothe-
sized that also PFASs might have cardiovascular eﬀects in the general
population. We measured several PFASs in plasma from a population-
based sample of almost 1000 elderly men and women (50% women) in
the Prospective Investigation of the Vasculature in Uppsala Seniors
(PIVUS-study) (Lind et al., 2005), with the hypothesis that elevated
levels of PFASs are related to atherosclerosis measured by ultrasound
in the carotid arteries in this cross-sectional study. Since previous
studies have pointed towards a gender diﬀerence in the elimination of
PFASs (Kudo et al., 2002), and that PFASs might eﬀect sex hormones
(Joensen et al., 2013), we paid special attention to the possibility that
eﬀects of PFASs on atherosclerosis are sex-speciﬁc.
We used three diﬀerent indices of atherosclerosis in the present
study. First, a local thickening of the intima-media complex, which is
considered an established atherosclerotic plaque. Second, the intima-
media thickness (IMT) in the common carotid artery, which is a
common measure of early atherosclerosis, but that could also be
increased by media hypertrophy. Third, the echogenicity of the
intima-media complex (denoted the intima-media grey scale median,
IM-GSM), a measure of the structural composition of the arterial wall.
The latter two indices are used as indicators of early changes in the
carotid artery.
2. Material and methods
2.1. Subjects
Eligible were all subjects aged 70 living in the community of
Uppsala, Sweden. The subjects were chosen from the register of
community living and were invited in a randomized order. The subjects
received an invitation by letter within 2 months of their 70th birthday.
Of the 2025 subjects invited, 1016 subjects participated giving a
participation rate of 50.1%. The investigation was conducted between
2001 and 2004.
The study was approved by the Ethics Committee of the University
of Uppsala and the participants gave informed consent prior to the
study.
Basic characteristics of the sample is given in Table 1.
2.2. Basic characteristics and cardiovascular risk factors
The participants were asked to answer a questionnaire about their
medical history, smoking habits and regular medication. Regarding
medical history, the participants were asked if they have been given a
diagnosis by a physician regarding a list of diagnoses. The smoking
question was coded as current or no current smoking. All subjects were
investigated in the morning after an over-night fast. No medication or
smoking was allowed after midnight. After recordings of height, weight,
abdominal and hip circumference, an arterial cannula was inserted in
the brachial artery for blood sampling and later regional infusions of
vasodilators (not dealt with in the present study). Blood pressure was
measured by a calibrated mercury sphygmomanometer in the non-
cannulated arm to nearest mmHg after at least 30 min of rest and the
average of three recordings was used. Lipid variables and fasting blood
glucose were measured by standard laboratory techniques.
As the participation rate in baseline investigation of this cohort was
only 50%, we carried out an evaluation of cardiovascular disorders and
medications in 100 consecutive non-participants. The prevalence of
cardiovascular drug intake, history of myocardial infarction, coronary
revascularization, antihypertensive medication, statin use and insulin
treatment were similar to those in the investigated sample, while the
prevalence of diabetes, congestive heart failure and stroke tended to be
Table 1
Basic characteristics and major cardiovascular risk factors in the sample (n=1016).
Means with SD or proportions are given in parenthesis.
Total sample Women Men
n 1016 509 507
Variable Mean (SD) Mean (SD) Mean (SD)
Height (cm) 168.96 (9.12) 162.14
(5.63)
175.79 (6.45)
Weight (kg) 77.32 (14.42) 71.17
(13.12)
83.49 (12.97)
Waist circumference (cm) 91.16 (11.58) 87.6 (11.56) 94.74 (10.45)
BMI (kg/m2) 27.03 (4.33) 27.08 (4.88) 26.99 (3.71)
SBP (mmHg) 149.63
(22.68)
153.3 (22.6) 145.95
(22.18)
DBP (mmHg) 78.68 (10.18) 78.03
(10.08)
79.33 (10.25)
Serum cholesterol (mmol/l) 5.43 (1.02) 5.72 (0.97) 5.14 (0.98)
LDL-cholesterol (mmol/l) 3.38 (0.88) 3.52 (0.86) 3.24 (0.87)
HDL-cholesterol (mmol/l) 1.51 (0.43) 1.66 (0.43) 1.36 (0.37)
Serum triglycerides (mmol/l) 1.28 (0.6) 1.27 (0.58) 1.29 (0.62)
Fasting blood glucose (mmol/l) 5.3 (1.6) 5.2 (1.5) 5.4 (1.6)
Current smoking (%) 0.11 (0.31) 0.11 (0.32) 0.1 (0.3)
Statin treatment (%) 15 13 16
Antihypertensive treatment (%) 31 31 31
Diabetes mellitus (%) 12 10 14
Myocardial infarction (%) 7 3 11
Stroke (%) 4 2 5
Heart failure (%) 4 3 5
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higher among the non-participants (see reference Lind et al., 2005 for
details).
2.3. Carotid artery ultrasound evaluation
The carotid artery was assessed by external B-mode ultrasound
imaging (Acuson XP128 with a 10 MHz linear transducer, Acuson
Mountain View, California, USA). The common carotid artery (CCA),
the bulb and the internal carotid artery (ICA) were visualized and the
occurrence of plaque was recorded on both sides. A plaque was
considered to be present if the intima media thickness (IMT) was
locally thickened more than 50% compared to the surrounding IMT
(Hulthe et al., 1997). The numbers of carotid arteries with plaques (0, 1
or 2) were recorded.
The images were digitized and imported into the AMS (Artery
Measurement Software) automated software for dedicated analysis of
intima-media thickness and the grey scale median of the intima-media
complex (Liang et al., 2000). The IMT was evaluated in the far wall in
the CCA 1–2 cm proximal to the bulb. A maximal 10 mm segment with
good image quality was chosen for intima-media thickness -analysis
from the carotid artery. The programme automatically identiﬁes the
borders of the intima-media thickness of the far wall and the inner
diameter of the vessel and calculates intima-media thickness and the
diameter from around 100 discrete measurements through the 10 mm
long segment. This automated analysis could be manually corrected if
not found appropriate at visual inspection. The given value for carotid
artery intima-media thickness is the mean value from both sides. Thus,
the IMT is a measure of the thickness of the artery wall, not including
the adventitia, but only the intima and media layers of the wall.
A region of interest was placed manually around the intima-media
segment that was evaluated for intima-media thickness and the
programme calculates the echogenicity in the intima-media complex
from analysis of the individual pixels within the region of interest on a
scale from 0 (black) to 256 (white). The blood was used as the reference
for black and the adventitia was the reference for white. The grey scale
median (GSM)-value given is the mean value from both sides (intima-
media grey scale median, IM-GSM). Thus, a low value of IM-GSM is
thought of as a marker of lipid inﬁltration in the carotid artery wall, the
ﬁrst step in carotid plaque formation.
The mean length of the evaluated intima-media segments was 9.0
(SD 2.1) mm when subjects with a segment recording less than 5 mm
were excluded. The measurements of intima-media thickness were
repeated in 30 random subjects giving a coeﬃcient of variation of
carotid artery intima-media thickness of 7.2% and 7.5% for IM-GSM.
2.4. Methods for the chemical analysis of the PFASs
The analytical method used to determine plasma concentrations of
PFASs in all samples (N=1, 016) was successfully validated in terms of
recovery, accuracy, and precision (Salihovic et al., 2015, 2013). Brieﬂy,
150 µL serum extracts were analyzed using an automated column-
switching ultra-performance liquid chromatography-tandem mass
spectrometry (HPLC-MS/MS) method for determination of PFASs.
The current study evaluated the 8 PFASs for which > 80% of the
population showed measurable levels above the lower level of detec-
tion; perﬂuoroheptanoic acid (PFHpA), perﬂuorononanoic acid
(PFNA), perﬂuorodecanoic acid (PFDA), perﬂuoroundecanoic acid
(PFUnDA), perﬂuorohexane sulfonic acid (PFHxS), linear isomer of
perﬂuorooctane sulfonic acid (L-PFOS), perﬂuorooctanoic acid (PFOA)
and perﬂuorooctane sulfonamide (PFOSA). The analytical procedure
involves rapid protein precipitation using 96-well plates followed by
instrumental analyses on a Acquity UPLC coupled to a Quattro Premier
XE HPLC-MS/MS system (Waters Corporation, Milford, USA) with an
atmospheric electrospray interface operating in negative ion mode
system by injecting a 250 µL aliquot of the sample onto a C18
(2.1×20 mm, 2.5 µm) trap column connected to a C18 (2.1×100 mm,
1.7 µm) analytical column by a 6-port column switch valve.
Quantitative analysis of the PFASs was performed using the internal
standard method; all standards (i.e., 13C labeled internal standards, 13C
labeled recovery standards and native calibration standards) were
purchased from Wellington Laboratories (Guelph, Ontario, Canada).
The method detection limits ranged between 0.01 and 0.17 ng mL−1
depending on the analyte. Medians and 25th and 75th percentile of the
eight diﬀerent PFASs with detectable levels (ng mL−1) in > 75% of the
subjects are given in Suppl Table 1.
2.5. Statistical analyses
All eight PFASs were skewed towards high levels, but were normally
distributed following ln-transformation. Relationships between PFASs
and number of carotid arteries with plaque (0, 1 or 2) were evaluated
by ordinal logistic regression models, ﬁrst using the PFASs as linear
variables, and thereafter using the squared form of the PFASs to search
for non-linear eﬀects. For the continuous analysis, two steps of
adjustments were used. First, adjustment for gender only, and secondly
multiple adjustment for gender, LDL and HDL-cholesterol and serum
triglycerides, BMI, blood pressure, smoking and exercise habits, energy
and alcohol intake, diabetes and educational level. Of the 12 variables
included in the model in the multiple adjustment, smoking and
exercise habits, energy and alcohol intake, and educational level are
life-style factors with the potential to inﬂuence PFASs levels, as well as
indices of atherosclerosis. LDL and HDL-cholesterol and serum
triglycerides, BMI, blood pressure and diabetes are classical risk factors
for atherosclerosis, but it is less obvious that those variables could
aﬀect PFASs levels. Some of those, like cholesterol, have been linked to
PFASs and could eventually be a mediator in the PFASs vs. athero-
sclerosis relationship.
A similar approach was used when relating PFASs to either IMT or
IM-GSM. In this analysis, linear regression analysis was performed.
In order to search for sex-speciﬁc relationships, interaction terms
between sex and the 8 PFASs were created and included in a separate
set of models. If the interaction term was signiﬁcant, analyses were also
performed in men and women separately.
Structural equation models (SEM) were used to disentangle the role
of mediation of serum cholesterol on the relationships between PFASs
and indices of atherosclerosis.
STATA14 (Stata corp, College Station, TX, USA) was used for
calculations.
3. Results
The mean value for IMT was 0.88 mm (0.16 SD), while the
corresponding mean value for IM-GSM was 79 (23 SD). In the total
sample, 273 subjects showed bilateral plaque, 343 showed unilateral
plaque and 327 were free of carotid plaque.
As could be seen in Table 2, no consistent signiﬁcant linear
associations were seen between the PFASs and IMT or IM-GSM when
men and women were analyzed together (and adjusting for sex).
Neither was occurrence of plaques in the carotid arteries related to
PFASs levels (Table 4).
Introduction of a quadratic term for the PFASs in the model did not
disclose any consistent signiﬁcant non-linear relationships.
However, a highly signiﬁcant interaction between sex and some of
the PFCAs were seen regarding IM-GSM (p=0.002 for PFNA and
PFDA, p=0.0004 for PFUnDA). When men and women were analyzed
separately, PFNA, PFDA, and PFUnDA were all related to IM-GSM in a
positive fashion in women (beta 6.023, 95%CI (2.06, 9.986), p=0.003
for PFNA, 7.546, (2.622, 12.47), p=0.003 for PFDA and 7.045, (2.602,
11.488), p=0.002 for PFUnDA), while these relationships were nega-
tive in men (although only signiﬁcantly so for PFUnDA, beta −4.574,
(−9.092, −0.057), p=0.047, Fig. 1). Following adjustment for multiple
risk factors these gender diﬀerences persisted, although at this stage
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only the association between PFNA and IM-GSM was still signiﬁcant in
women (beta 5.268, (1.048, 9.489), p=0.014). For details, see Table 3.
Unadjusted analyses of the eight PFASs vs the three markers of
atherosclerosis is given in Suppl Table 2.
Since PFASs repeatedly have been shown to be related to choles-
terol metabolism, we further investigated if the above-described
relationship between PFUnDA and IM-GSM in women was mediated
by cholesterol in a SEM analysis. This analysis disclosed that 3.4% of
the total eﬀect of PFUnDA on IM-GSM in women was mediated by
cholesterol (p=0.012). For men, the corresponding proportion of the
total eﬀect of PFUnDA on IM-GSM being mediated by serum choles-
terol was 1.7% (p=0.014).
A highly signiﬁcant interaction between sex and some of the PFASs
were seen also regarding carotid plaques (p=0.006 for PFOSA, p=0.005
for PFUnDA). In this case, PFUnDA was signiﬁcantly related to carotid
plaque in women (OR 1.59, 95%CI (1.03, 2.43), p=0.034, Fig. 2), but
not in men (0.93, (0.62, 1.42), p=0.74). A similar tendency was seen for
PFOSA (OR 1.28, (0.98, 1.66), p=0.07 in women and 0.99, (0.75, 1.29),
p=0.91 in men). For details, see Table 5.
We further investigated if the above-described relationship between
PFUnDA and carotid plaques in women was mediated by cholesterol in
a SEM analysis. This analysis disclosed no signiﬁcant mediation of
serum cholesterol on the PFUnDA vs. carotid plaques relationship
(p=0.18).
In order to evaluate if common cardio-metabolic medications used
in the elderly inﬂuenced the above-mentioned signiﬁcant relationship,
we included statins, beta-blockers, calcium antagonists, ACE-inhibi-
tors, diuretics, insulin, oral antidiabetic agents in the models, but
inclusion of those medications had only marginal eﬀects of the
signiﬁcant relationships described above.
The mean glomerular ﬁltration rate (GFR), as calculated by the
Cockcroft-Gault equation, was 81 (SD 20) ml/in/m2 in the sample,
with 15% showing a GFR< 60 ml/in/m2. Including GFR in the models
for the above-mentioned signiﬁcant relationships did however only
have marginal eﬀects on these signiﬁcant relationships.
4. Discussion
The present cross-sectional study showed that the long-chain
PFASs, especially PFUnDA, were related to echogenicity of the carotid
artery wall and to overt atherosclerotic plaque in women. We have
Table 2
Relationships between eight different PFASs (all ln-transformed) and the intima-media
thickness (IMT) (at top) and the echogenicity of the intima-media complex (IM-GSM)
(below). Relationships are given both for sex-adjusted and multiple adjusted analysis
(gender, HDL- and LDL-cholesterol and serum triglycerides, BMI, blood pressure,
smoking exercise habits, energy and alcohol intake, diabetes and educational level). The
regression coefficients (Beta), 95%CI and p-values are given for the linear models.
PFASs; perfluoroheptanoic acid (PFHpA), perfluorooctanoic acid (PFOA), perfluorono-
nanoic acid (PFNA), perfluorodecanoic acid (PFDA), perfluoroundecanoic acid (PFUn-
DA), perfluorohexane sulfonic acid (PFHxS), linear isomer of perfluorooctane sulfonic
acid (L-PFOS), as well as perﬂuorooctane sulfonamide (PFOSA).
Sex adjusted Multiple adjusted
Beta (95% CI) P-value Beta (95% CI) P-value
IMT
PFHpA 0.001 (−0.014, 0.014) 0.99 0.002 (−0.012, 0.016) 0.78
PFHxS −0.006 (−0.021,
0.008)
0.41 0.001 (−0.014, 0.016) 0.90
L-PFOS 0.003 (−0.015, 0.021) 0.76 0.003 (−0.015, 0.022) 0.72
PFOA −0.002 (−0.025,
0.021)
0.84 0.007 (−0.017, 0.03) 0.58
PFNA 0.01 (−0.011, 0.03) 0.37 0.003 (−0.018, 0.025) 0.76
PFDA 0.001 (−0.026, 0.026) 0.99 0.003 (−0.0025, 0.03) 0.85
PFOSA 0.012 (−0.006, 0.031) 0.18 0.024 (0.006, 0.042) 0.01
PFUnDA −0.004 (−0.027, 0.02) 0.77 −0.001 (−0.027,
0.026)
0.96
IM-GSM
PFHpA 0.369 (−1.507, 2.245) 0.70 0.471 (−1.481, 2.424) 0.64
PFHxS 0.04 (−1.863, 1.943) 0.97 −0.541 (−2.522,
1.441)
0.59
L-PFOS 1.443 (−0.789, 3.675) 0.21 1.238 (−1.103, 3.578) 0.30
PFOA 1.475 (−1.501, 4.452) 0.33 0.933 (−2.206, 4.072) 0.56
PFNA 1.315 (−1.427, 4.056) 0.35 1.915 (−0.996, 4.825) 0.20
PFDA 1.591 (−1.861, 5.043) 0.37 0.258 (−3.528, 4.044) 0.89
PFOSA 1.675 (−0.45, 3.8) 0.12 0.455 (−1.741, 2.651) 0.68
PFUnDA 1.071 (−2.116, 4.257) 0.51 −0.393 (−3.99, 3.205) 0.83
Table 3
Relationships between eight different PFASs (all ln-transformed) and the intima-media
thickness (IMT) (at top) and the echogenicity of the intima-media complex (IM-GSM)
(below) in sex-stratified analyses. Relationships are given for non-adjusted and multiple
adjusted analyses (HDL- and LDL-cholesterol and serum triglycerides, BMI, blood
pressure, smoking exercise habits, energy and alcohol intake, diabetes and educational
level). The regression coefficients (Beta), 95%CI and p-values are given for the linear
models. For abbreviations of PFASs, see Table 2.
Non-adjusted Multiple adjusted
Beta (95% CI) P-value Beta (95% CI) P-value
IMT
Males
PFHpA 0.001 (−0.018, 0.021) 0.90 −0.004 (−0.024,
0.017)
0.71
PFHxS −0.004 (−0.026, 0.019) 0.75 0.004 (−0.019, 0.027) 0.73
L-PFOS 0.001 (−0.021, 0.024) 0.90 0.004 (−0.019, 0.028) 0.72
PFOA 0.006 (−0.025, 0.037) 0.72 0.013 (−0.02, 0.045) 0.44
PFNA 0.012 (−0.017, 0.04) 0.420 0.005 (−0.025, 0.035) 0.75
PFDA −0.005 (−0.041, 0.031) 0.80 −0.009 (−0.049,
0.03)
0.64
PFOSA 0.005 (−0.02, 0.031) 0.70 0.013 (−0.014, 0.039) 0.35
PFUnDA −0.009 (−0.043, 0.025) 0.60 −0.015 (−0.053,
0.023)
0.43
Females
PFHpA −0.001 (−0.021, 0.018) 0.88 0.009 (−0.011, 0.029) 0.39
PFHxS −0.008 (−0.027, 0.011) 0.40 −0.001 (−0.02,
0.018)
0.93
L-PFOS 0.005 (−0.025, 0.036) 0.73 0.006 (−0.025, 0.037) 0.70
PFOA −0.013 (−0.047, 0.021) 0.46 0.001 (−0.034, 0.035) 0.97
PFNA 0.007 (−0.024,0 0.038) 0.68 0.003 (−0.029, 0.035) 0.84
PFDA 0.005 (−0.031, 0.042) 0.77 0.021 (−0.019, 0.06) 0.30
PFOSA 0.021 (−0.005, 0.047) 0.12 0.039 (0.012, 0.065) 0.004
PFUnDA 0.002 (−0.031, 0.035) 0.89 0.019 (−0.018, 0.056) 0.307
IM-GSM
Males
PFHpA −1.842 (−4.483, 0.799) 0.17 −0.859 (−3.648,
1.93)
0.55
PFHxS −0.991 (−3.868, 1.886) 0.50 −1.298 (−4.339,
1.742)
0.40
L-PFOS 0.524 (−2.417, 3.465) 0.73 1.366 (−1.814, 4.545) 0.40
PFOA −1.09 (−5.191, 3.011) 0.60 −0.582 (−4.974,
3.81)
0.80
PFNA −2.569 (−6.344, 1.207) 0.18 −0.902 (−4.98,
3.176)
0.66
PFDA −3.596 (−8.405, 1.214) 0.14 −3.303 (−8.672,
2.067)
0.23
PFOSA 0.915 (−2.092, 3.923) 0.55 0.329 (−2.875, 3.532) 0.84
PFUnDA −4.574 (−9.092,
−0.057)
0.05 −4.405 (−9.52, 0.71) 0.09
Females
PFHpA 2.834 (0.178, 5.49) 0.04 2.18 (−0.608, 4.967) 0.13
PFHxS 0.915 (−1.612, 3.442) 0.48 −0.085 (−2.737,
2.567)
0.95
L-PFOS 2.833 (−0.626, 6.291) 0.11 1.068 (−2.51, 4.647) 0.56
PFOA 4.644 (0.313, 8.976) 0.04 2.72 (−1.875, 7.315) 0.25
PFNA 6.023 (2.06, 9.986) 0.003 5.268 (1.048, 9.489) 0.01
PFDA 7.546 (2.622, 12.47) 0.0028 4.09 (−1.353, 9.533) 0.14
PFOSA 2.639 (−0.373, 5.652) 0.09 0.438 (−2.646, 3.522) 0.78
PFUnDA 7.045 (2.602, 11.488) 0.002 3.948 (−1.23, 9.126) 0.14
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previously shown that atherosclerosis is associated with other environ-
mental contaminants, like the PCBs (Lind et al., 2012b), some
phthalates (Lind and Lind, 2011), as well as some metals (Lind et al.,
2012a). The present study adds to that prior knowledge that several
environmental contaminants with very diﬀerent chemical properties,
diﬀerent mechanisms of action and diﬀerent degrees of exposure are
linked to atherosclerosis in the carotid arteries.
4.1. Carotid artery plaque
Presence of atherosclerotic plaques in the carotid arteries is a
known predictor of future CV events (O'Leary et al., 1999).
Atherosclerosis in the carotid arteries is also known to be predictive
for plaques in the coronary circulation (Hulthe et al., 1997). Thus,
subjects with carotid artery plaques are at increased risk also for
myocardial infarction. The presently found association between
PFUnDA levels and carotid artery plaque in women is therefore of
concern. Why this relationship only is seen in women is not known, but
it has recently been found that a high level of PFOS is related to sex
hormone levels (Joensen et al., 2013). Since sex hormones seem
capable to modulate the development of atherosclerosis (Naessen
et al., 2012) it is not unlikely that PFASs could aﬀect men and women
in diﬀerent ways.
4.2. Echogenicity of the intima-media complex
The echogenicity of the intima-media complex is closely related to
the echogenicity on overt plaques (Lind et al., 2007), and has been
shown to be a powerful predictor of future CV mortality (Wohlin et al.,
2009). The echogenicity of overt plaques has been shown to be related
to the structural composition of the plaque (El-Barghouty et al., 1996),
and it is therefore likely that also the echogenicity of the intima-media
complex is a marker of composition of the vascular wall. In this case it
Table 4
Relationships between eight different PFASs (all ln-transformed) and number of carotid
arteries with atherosclerotic plaques. Relationships are given both for sex-adjusted and
multiple adjusted analysis (sex, HDL- and LDL-cholesterol and serum triglycerides, BMI,
blood pressure, smoking exercise habits, energy and alcohol intake, diabetes and
educational level). The odds ratios (OR), 95%CI and p-values are given for the
relationships. For abbreviations of PFASs, see Table 2.
Sex adjusted Multiple adjusted
OR (95% CI) P-value OR (95% CI) P-value
PFHpA 0.92 (0.79, 1.08) 0.32 0.95 (0.81, 1.13) 0.59
PFHxS 1.08 (0.94, 1.25) 0.28 1.11 (0.95, 1.29) 0.18
L-PFOS 1.07 (0.93, 1.21) 0.34 1.07 (0.94, 1.22) 0.32
PFOA 0.92 (0.75, 1.13) 0.45 0.95 (0.77, 1.18) 0.67
PFNA 1.02 (0.84, 1.24) 0.85 1.09 (0.88, 1.34) 0.43
PFDA 0.99 (0.74, 1.32) 0.94 1.1 (0.81, 1.51) 0.54
PFOSA 1.09 (0.91, 1.3) 0.36 1.13 (0.94, 1.37) 0.19
PFUnDA 1.06 (0.81, 1.39) 0.65 1.2 (0.9, 1.62) 0.22
Fig. 1. Relationship between circulating levels of PFUnDA (on a ln-scale, ng mL−1) and
the echogenicity of the intima-media complex (IM-GSM) in women (FIGURE 1A,
p=0.002) and in men (FIGURE 1B, p < 0.05). The predictive margins (and 95%CI) for
IM-GSM is given at the y-axis.
Fig. 2. Relationship between circulating levels of PFUnDA (on a ln-scale, ng mL−1) and
carotid artery plaque in women (p < 0.05). The predictive margins (and 95%CI) for the
probability of have carotid artery plaque (and 95%CI) is given at the y-axis.
Table 5
Relationships between eight different PFASs (all ln-transformed) and number of carotid
arteries with atherosclerotic plaques in sex-stratified analyses. Relationships are given
for multiple adjusted analyses (HDL- and LDL-cholesterol and serum triglycerides, BMI,
blood pressure, smoking exercise habits, energy and alcohol intake, diabetes and
educational level). The odds ratios (OR), 95%CI and p-values are given for the
relationships. For abbreviations of PFASs, see Table 2.
Males Females
Variable OR (95% CI) P-value OR (95% CI) P-value
PFHpA 0.83 (0.66, 1.05) 0.12 1.11 (0.86, 1.41) 0.42
PFHxS 1.19 (0.94, 1.51) 0.16 1.06 (0.87, 1.29) 0.56
L-PFOS 1.09 (0.89, 1.35) 0.41 1.05 (0.88, 1.25) 0.59
PFOA 0.95 (0.68, 1.31) 0.74 0.96 (0.72, 1.27) 0.77
PFNA 1.11 (0.81, 1.51) 0.52 1.07 (0.8, 1.42) 0.64
PFDA 0.97 (0.63, 1.49) 0.89 1.29 (0.82, 2.04) 0.27
PFOSA 0.99 (0.75, 1.29) 0.92 1.28 (0.98, 1.66) 0.07
PFUnDA 0.93 (0.62, 1.42) 0.75 1.59 (1.03, 2.43) 0.03
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is likely that an echolucent (dark) intima-media complex is indicative
of lipid inﬁltration, while an echogenic (white) intima-media complex
possibly represent collagen disposition.
In the present study, some of the PFASs, more speciﬁcally the long-
chain PFCAs showed positive relationships vs. IM-GSM in women, but
the opposite tendency in men. Thus, most likely these PFCAs are
related to an increased lipid inﬁltration in the vascular wall in men, but
more ﬁbrous (collagen) tissue in women. How this translates in terms
of risk is hard to tell, since both a low and a high IM-GSM were related
to an increased risk (Wohlin et al., 2009).
4.3. Intima-media thickness
IMT is known as a predictor of CV events, and is usually regarded as
a marker of atherosclerosis (O'Leary et al., 1999). However, athero-
sclerosis is a disorder of the intima, but IMT is also incorporating the
media in the measurement. In the present study, no associations were
seen between the PFASs and IMT. This is in contrast to the study by
Lin et al who found an association between PFOS levels and IMT in
younger subjects (Lin et al., 2013). The diﬀerences in age between the
studies might have contributed to the diverse ﬁndings. Of interest is the
ﬁnding of Lin et al that the relationship between PFASs and IMT was
mainly found in women, in accordance with ﬁndings in the present
study.
4.4. Other environmental contaminants
Since we previously have reported other environmental contami-
nants, like the PCBs (Lind et al., 2012b), some phthalates (Lind and
Lind, 2011), as well as some metals (Lind et al., 2012a) to be related to
indices of atherosclerosis, we added PCB209, Cr, Ni, Al, mono-methyl
phthalate (MMP) and bisphenol A (BPA) to the models investigating
the PFUnDA vs. IM-GSM or carotid plaque relationships, but addition
of these other environmental contaminants did not change the
PFUnDA vs. IM-GSM or carotid plaque relationships to any signiﬁcant
degree. This is well in line with previous observations that these major
environmental contaminants are not closely related and in order to
obtain information on the eﬀect of environmental contaminants on a
phenotype like atherosclerosis, many diﬀerent contaminants have to be
evaluated (Lampa et al., 2012).
4.5. Potential mechanisms of action
There is no well known obvious explanation for an eﬀect of PFASs
on atherosclerosis. PFASs are known to be agonists for the PPAR alpha
and gamma receptors (Lau et al., 2007), although the diﬀerent PFASs
diﬀer regarding binding to these two types of PPAR receptors.
Activation of PPAR alpha and gamma-receptors could be diﬀerent
mechanisms be involved in diﬀerent steps in glucose homeostasis, such
as inﬂuence on insulin resistance (Lebovitz and Banerji, 2001) and
insulin secretion (Lupi et al., 2004), as well as inﬂuence circulating
levels of lipids (Thomas et al., 2007) and altering the amount of
abdominal fat (Moon et al., 2011; Thomas et al., 2007). In line with this
knowledge is our previous ﬁndings that some, but not all, of the
measured PFASs were related to diabetes in the present sample (Lind
et al., 2014). Diabetes, dyslipidemia and obesity are all known risk
factors for atherosclerosis development, but in the present study the
association between the PFASs and atherosclerosis was seen indepen-
dently of these risk factors.
It was mainly the long-chained PFASs that were related to indices of
atherosclerosis in the present study, despite that lower concentrations
generally were seen for those PFASs. This is hard to explain from
experimental data, since it has been shown that PPAR alpha activation
occurred in an additive fashion when diﬀerent PFASs were added to
PFOA (Wolf et al., 2014), a PFASs with higher concentration than
PFUnDA. Structurally, PFUnDA is the 11 carbon version of PFOA and
because of its longer carbon chain PFUnDA is more bioaccumulative
(Zhang et al., 2013). The few available mechanistic studies of PFUnDA
found, in line with previous research of other PFASs, that PFUnDA
activated the PPAR alpha receptor and inhibited the function of the
thyroid hormone (Long et al., 2013; Takahashi et al., 2014). Moreover,
Long et al. (2013) also investigated the eﬀect of PFAAs on the aryl
hydrocarbon receptor and found that PFDA and PFDoDA elicited an
activating eﬀect but not PFUnDA Thus, no PFUnDA-speciﬁc eﬀects
have been reported in the available literature. Overall, further experi-
mental studies with regard to PFUnDA and the other long-chain PFCAs
are required to gain a deeper insight to the mechanistic pathway by
which PFUnDA exerts eﬀects on the arterial wall.
A number of alterations in the immune system, such as T-cell-
dependent antibody responses (DeWitt et al., 2016), interferon-gamma
expression (Ryu et al., 2014), toll-like receptor 2 (TLR2) expression
and activation of interleukins by the NF-κB pathway (Zhang et al.,
2014), and a reduction in IgM antibodies (DeWitt et al., 2016), have
been linked to PFASs exposure. As reviewed by (Libby and Hansson,
2015) an immune reaction against lipid inﬁltration and trapping in the
arterial wall is an early and very important event in the development of
atherosclerosis. Future experimental studies have to guide which of
these immunological eﬀects of PFASs that could be involved in
atherosclerosis development.
It has repeatedly been shown that PFASs levels in humans are
related to cholesterol metabolism (Nelson et al., 2010; Skuladottir
et al., 2015; Winquist and Steenland, 2014). In order to test if an eﬀect
of PFASs on atherosclerosis is mediated by the eﬀect of PFASs on
cholesterol, we performed SEM analyses on the major ﬁndings in this
study. That analyses disclosed that the mediating role of serum
cholesterol signiﬁcant, but very small (1–3%), regarding the PFUnDA
vs. IM-GSM relationship, and not signiﬁcant regarding the PFUnDA vs.
plaque relationship. Thus, in this study, serum cholesterol was not a
major mediator of the PFASs vs. atherosclerosis relationship.
In a very recent paper by Lin et al (Lin et al., 2016) it was shown
that PFOS was related to circulating microparticles (both endothelium
and platelet-derived), as well as to IMT. Furthermore, the link between
PFOS and IMT was closer in those with elevated levels of micropar-
ticles. Endothelium and platelet-derived microparticles are markers of
apoptosis and are linked to endothelial dysfunction, an early feature of
atherosclerosis. Thus, with that study a link between PFASs and early
atherosclerosis is established.
4.6. Limitation of the study
The present sample is limited to Caucasians aged 70. Therefore,
caution should be made to draw conclusions to other ethnic and age
groups. The present study had a moderate participation rate. However,
an analysis of non-participants showed the present sample to be fairly
representative of the total population regarding most cardiovascular
disorders and drug intake. Furthermore, many statistical tests were
performed and thus the present ﬁndings since we liked to include not
only the most commonly analyzed PFASs, PFOS and PFOA, and we
included not only the most commonly used marker of carotid athero-
sclerosis, IMT, but also information on overt plaques and also on the
echogenicity of the arterial wall, IM-GSM, to investigate early changes
in the atherosclerotic process. Given the prior limited knowledge in this
area on the possible diﬀerent actions of diﬀerent PFASs on the
vasculature, it was very hard to make any speciﬁc prior hypothesis
on which PFASs that would be related to a speciﬁc marker of
atherosclerosis. Using this approach to give a more detailed picture
of the relationship between multiple PFASs and three markers of
atherosclerosis must hopefully be more valuable than just analyzing
two PFASs and IMT, but could produce false positive results due to
multiple statistical testing. Our ﬁndings must therefore be regarded as
exploratory and must therefore be taken with caution until reproduced
by others. The ﬁnding that two diﬀerent markers of atherosclerosis,
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overt plaque and IM-GSM were associated with some PFASs in a fairly
consistent manner does however make the present ﬁndings likely not to
be merely chance ﬁndings.
Cross-sectional studies could always be subjected to reverse causa-
tion, so ideally prospective studies on plaque progression and devel-
opment of atherosclerosis-related disorders, such as myocardial in-
farction and stroke, should be carried out.
4.7. Conclusions
In conclusion, in this cross-sectional study, a pronounced gender
diﬀerence was seen regarding associations between some of the PFASs,
especially the long-chain PFCAs such as PFUnDA, and markers of
atherosclerosis, with more pronounced relationships found in women.
These ﬁndings suggest a role for PFASs in atherosclerosis.
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